Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Cytostatic activity of novel primaquine-vorinostat hybrid drugs (CROSBI ID 659332)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | domaća recenzija

Mlinarić, Zvonimir ; Beus, Maja ; Antunović, Maja ; Marijanović, Inga ; Rajić Džolić, Zrinka ; Zorc, Branka Cytostatic activity of novel primaquine-vorinostat hybrid drugs // Knjiga sažetaka / Vrsaljko, Domagoj ; Dejanović, Igor ; Žižek, Krunoslav (ur.). Zagreb: Hrvatsko društvo kemijskih inženjera i tehnologa (HDKI), 2018. str. 173-173

Podaci o odgovornosti

Mlinarić, Zvonimir ; Beus, Maja ; Antunović, Maja ; Marijanović, Inga ; Rajić Džolić, Zrinka ; Zorc, Branka

engleski

Cytostatic activity of novel primaquine-vorinostat hybrid drugs

Some of the most important epigenetic modifications are carried out by human histone deacetylases (HDACs). Vorinostat (SAHA) is a known and registered anticancer drug, which inhibits human histone deacetylases. On the other hand, primaquine, a well-known antimalarial drug, has certain anticancer activity, especially against MCF-7 cell line [1]. That prompted us to design sahaquines, primaquine-SAHA conjugates, which could lead to potent anticancer activity against specific cancer cell lines. To fully test our hypothesis, the following features were varied: the length and type of the linker between PQ and hydroxamic acid moiety, as well as the substitution of the hydroxamic acid moiety, leading to 4 different classes of derivatives. The cytostatic activities of synthesized compounds were tested on four different human cancer cell lines: glioblastoma (A1235), hepatocellular carcinoma (Hep G2), breast adenocarcinoma (MCF-7) and osteosarcoma (U2OS), while the potential toxicity was tested on human kidney cell line HEK-293. In both tests results were compared with primaquine and a registered cytostatic agent cisplatin. Compound 5b was shown to be the most active against MCF- 7 (IC50 0.8 ± 0.4 µM), while other compounds had IC50 ranging from 3.9 ± 1.5 µM to 16.6 ± 0.8 µM. Against Hep G2, none of the tested compounds showed high activity, 4d being the most potent (IC50 9.9 ± 1.1 µM). Activity against U2OS varied much: 5b and 4e showed strong activity (IC50 3.30 ± 0.05 µM and 7.1 ± 1.2 µM, respectively), while other compounds showed moderate activity, 3c being the least active (IC50 33.8 ± 2.9 µM). Derivatives 5b and 5d showed strong activity against A1235 (IC50 3.5 ± 0.7 µM and 6.8 ± 0.1 µM, respectively). All compounds were found to be less toxic than primaquine and cisplatin when tested on HEK- 293.

primaquine ; vorinostat ; hybrid drugs ; cytostatic activity

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

173-173.

2018.

nije evidentirano

objavljeno

978-953-6894-62-8

Podaci o matičnoj publikaciji

Knjiga sažetaka

Vrsaljko, Domagoj ; Dejanović, Igor ; Žižek, Krunoslav

Zagreb: Hrvatsko društvo kemijskih inženjera i tehnologa (HDKI)

Podaci o skupu

XII. susret mladih kemijskih inženjera (SMLKI 2018)

poster

22.02.2018-23.02.2018

Zagreb, Hrvatska

Povezanost rada

Biologija, Farmacija